CompletedPhase 1NCT00793702
Safety and Risk of Sensitisation of the rdESAT-6 + rCFP-10 Skin Test Following Repeated Intradermal Administration
Studying Tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Statens Serum Institut
- Principal Investigator
- Pernille Nyholm TingskovStatens Serum Institut
- Intervention
- rdESAT-6 + rCFP-10(biological)
- Enrollment
- 42 enrolled
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2008 – 2009
Study locations (1)
- Rigshospitalet, Epidemiklinikken, Copenhagen, Denmark
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00793702 on ClinicalTrials.govOther trials for Tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07164742Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)Johns Hopkins University
- RECRUITINGNCT0707721318F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis PatientsChildren's Hospital Medical Center, Cincinnati
- RECRUITINGNCT07451899TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung DiseaseUniversitas Padjadjaran
- RECRUITINGNCT06845618Blood Tuberculosis DNA Levels to Monitor Tuberculosis TreatmentUniversity of Oxford
- ENROLLING BY INVITATIONNANCT06984887Evaluation of New TB Diagnostic Tests (NATs) in PakistanMercy Corps Pakistan
- RECRUITINGNCT07018076Candidate Clinical Correlate of Prognostic Outcome for TB StudyUniversity of California, San Francisco
- RECRUITINGNANCT07271225Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and VomitingIndonesia University
- RECRUITINGNCT06585358DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary TuberculosisKarolinska Institutet